DOI:
10.1055/s-00034924
Nuklearmedizin - NuclearMedicine
LinksClose Window
References
Ahmadzadehfar H, Eppard E, Kurpig S. et al.
Therapeutic response and side effects of repeated radioligand therapy with
177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate
cancer.
Oncotarget 2016;
7 (11) 12477-12488
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.